Feedstuffs is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Med-Pharmex settles FDA complaint

Med-Pharmex settles FDA complaint
Consent decree primarily relates to Med-Pharmex’s manufacturing of sterile animal drug products, which the company has voluntarily discontinued

Med-Pharmex, Inc. has announced the signing of a consent decree with the U.S. Food & Drug Administration, to settle and resolve the complaint for permanent injunction that the U.S. Department of Justice (DOJ) filed against Med-Pharmex in October 2020. The consent decree was subject to approval by the U.S. District Court for the Central District of California, which was approved, November 19.

The consent decree primarily relates to Med-Pharmex’s manufacturing of sterile animal drug products, which the company has voluntarily discontinued. Under the terms of the consent decree, Med-Pharmex will continue to manufacture and supply non-sterile animal drug products without interruption. Med-Pharmex said it is pleased with the outcome of this matter and will continue to ensure that all its products are safe and effective for their intended uses.

Med-Pharmex, Inc., a privately held company founded in 1983 in Pomona, California, develops and manufactures generic veterinary drug products. The company specializes in oral, topical, and injectable products for companion, equine, and food-producing animals, reaching its customers through veterinary distributors. The company said it is committed to continually discovering new products and serving the veterinary community with quality generic products at an affordable cost.

Source: Med-Pharmex

TAGS: Business
Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish